16
May
2023

Boundless Bio Gets $100M to Fight Cancer, NewLimit Gets $40M to Defy Aging

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

NEJM Study Linking Exercise, Cancer Recovery Raises Two Concerns: What If It’s Wrong?  What If It’s Right?
Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run
A Trek in the Himalayas for Cancer Research
ADCs: If at First You Don’t Succeed…